David R. Brenneman

Partner

David R. Brenneman represents clients with respect to the antitrust aspects of mergers & acquisitions (M&A), joint ventures, and other business combinations and has experience in a wide range of industries, including technology, telecommunications, life sciences, and financial services. David has coordinated pre-merger notifications and regulatory review around the world for hundreds of multimillion and multibillion dollar transactions, and has defended several high-profile transactions before the Antitrust Division of the US Department of Justice (DOJ) , the US Federal Trade Commission (FTC), and the European Commission. David also regularly provides counsel in other areas of antitrust law.

Extended Profile

David regularly counsels clients with respect to agency strategy and procedure; pre-merger conduct counseling; contract negotiations; merger control analysis, filings and approvals; and substantive advocacy before various competition law authorities in the US and abroad. David has guided clients through numerous DOJ and FTC investigations and second requests and has prepared Hart-Scott-Rodino (HSR) and other merger control filings for hundreds transactions. David frequently writes on topics concerning merger review and the HSR Act and his writings have appeared in Law360, The M&A Lawyer, and various American Bar Association publications, among others.

David is a member of the Morgan Lewis Committee on Foreign Investment in the United States (CFIUS) working group.

selected representations

David regularly represents two of the world’s 10 largest private equity groups in relation to merger control work. In addition, he has had leadership roles in obtaining antitrust approvals in several high profile and complicated transactions including:

Intercontinental Exchange in connection with its acquisition of Standard & Poor’s Securities and Evaluations business from McGraw Hill Financial (Department of Justice)
Pfizer Inc. in connection with its proposed $160 billion acquisition of Allergan plc (Federal Trade Commission)
Perrigo Company plc in connection with Mylan N.V.’s unsolicited offer to acquire Perrigo Company plc (Federal Trade Commission)
Pfizer Inc. in connection with its $68 billion acquisition of Wyeth (Federal Trade Commission)